German MPN-Registry for BCR-ABL 1-Negative Myeloid Neoplasms (Study Group Ulm)
To register a large number of patients with the diagnosis of a BCR-ABL 1- negative myeloid neoplasm (according to WHO 2008 / 2016 classification) in participating centers
To store samples from all patients (e.g. bone marrow aspirate, peripheral blood, plasma, and buccal swap, skin biopsy samples in exceptional cases)
To perform morphologic and genetic analyses
To assess clinical characteristics and outcome data using a defined catalogue containing clinically relevant variables
To assess biological disease features and correlate with clinical outcome data (prognostic and predictive markers)
To assess quality of life
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
To register a large number of patients with the diagnosis of a BCR-ABL 1- negative myeloid neoplasm (according to WHO 2008 / 2016 classification) in participating centers
To store samples from all patients (e.g. bone marrow aspirate, peripheral blood, plasma, and buccal swap, skin biopsy samples in exceptional cases)
To perform morphologic and genetic analyses
To assess clinical characteristics and outcome data using a defined catalogue containing clinically relevant variables
To assess biological disease features and correlate with clinical outcome data (prognostic and predictive markers)
To assess quality of life
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Frank Stegelmann, Dr.
- Phone Number: +4973150045521
- Email: frank.stegelmann@uniklinik-ulm.de
Study Locations
-
-
-
Augsburg, Germany, 86150
- Recruiting
- Hämatologische Onkologie Praxis Augsburg
-
Contact:
- Markus Bangerter, MD
- Phone Number: +498213446520
- Email: markus.bangerter@hop-augsburg.de
-
Augsburg, Germany, 86156
- Recruiting
- Klinikum Augsburg
-
Contact:
- Klaus Hirschbühl, MD
- Phone Number: +498214003715
- Email: klaus.hirschbuehl@klinikum-augsburg.de
-
Bad Saarow, Germany, 15526
- Recruiting
- Helios Klinikum, Bad Saarow
-
Contact:
- Daniel Schöndube, MD
- Phone Number: +493363173728
- Email: daniel.schoendube@helios-kliniken.de
-
Baden-Baden, Germany, 76532
- Recruiting
- Klinikum Mittelbaden
-
Contact:
- Jutta Hagemeyer, MD
- Phone Number: +497221/91-4126
- Email: j.hagemeyer@klinikum-mittelbaden.de
-
Coburg, Germany, 96450
- Recruiting
- MVZ Klinikum Coburg
-
Contact:
- Christof Lamberti, MD
- Phone Number: +49956122-34607
- Email: christof.lamberti@klinikum-coburg.de
-
Donauwörth, Germany, 86609
- Recruiting
- Donauwörth, Onko-Medeor
-
Contact:
- Dirk Hempel, MD
- Phone Number: +49906299939-0
- Email: donauwoerth@onko-medeor.de
-
Dresden, Germany, 01307
- Recruiting
- Onkologie, BAG, Dresden
-
Contact:
- Thomas Illmer, MD
- Phone Number: +493514400022
- Email: illmer@onkologie-dresden.de
-
Erding, Germany, 85435
- Recruiting
- Onkologie Erding
-
Contact:
- Stefanie Jilg, MD
- Phone Number: +49 8122 959139
- Email: stefanie.jilg@onkologie-erding.de
-
Freiburg, Germany, 79106
- Recruiting
- Universitätsklinikum Freiburg
-
Contact:
- Cornelius Waller, MD
- Phone Number: +497612700
- Email: cornelius.waller@uniklinik-freiburg.de
-
Greifswald, Germany, 17475
- Recruiting
- Universitätsklinikum Greifswald
-
Contact:
- Florian Heidel, MD
- Phone Number: +493834 - 86 22006
- Email: florian.heidel@med.uni-greifswald.de
-
Göppingen, Germany, 73035
- Recruiting
- Alb Fils Kliniken Göppingen
-
Contact:
- Martin Bommer, MD
- Phone Number: +497161642962
- Email: martin.bommer@af-k.de
-
Heidelberg, Germany, 69115
- Withdrawn
- Onkologische Praxis, Heidelberg
-
Heilbronn, Germany, 74072
- Withdrawn
- Onkologische Schwerpunktpraxis, Heilbronn
-
Herne, Germany, 44625
- Recruiting
- Marienhospital Bochum-Herne
-
Contact:
- Dirk Strumberg, MD
- Phone Number: +4923234991575
- Email: onkologie@marienhospital-herne.de
-
Jena, Germany, 07743
- Recruiting
- Universitätsklinikum Jena
-
Contact:
- Andreas Hochhaus, MD
- Phone Number: 9324216 03641
- Email: andreas.hochhaus@med.uni-jena.de
-
Kempten, Germany, 87439
- Recruiting
- Klinikum Kempten-Oberallgau gGmbH
-
Contact:
- Christian Langer, MD
- Phone Number: 2245 +49831530
- Email: christian.langer@klinikum-kempten.de
-
Landshut, Germany, 84036
- Recruiting
- Landshut VK&K Studien GbR
-
Contact:
- Ana Hoffmann, MD
- Phone Number: 429 087197403
- Email: ana.hoffmann@vehling-kaiser.de
-
Leer, Germany, 26789
- Active, not recruiting
- Leer, Studienzentrum Unter Ems
-
Leipzig, Germany, 04103
- Recruiting
- Universitätsklinikum Leipzig
-
Contact:
- Madlen Jentzsch, MD
- Phone Number: +493419713061
- Email: madlen.jentzsch@medizin.uni-leipzig.de
-
Magdeburg, Germany, 39120
- Recruiting
- Universitätsklinikum Magdeburg
-
Contact:
- Denise Wolleschak, MD
- Phone Number: +4916713134
- Email: denise.wolleschak@med.ovgu.de
-
Mannheim, Germany, 55131
- Recruiting
- Universitätsklinikum Mannheim
-
Contact:
- Andreas Reiter, MD
- Phone Number: +496213830
- Email: andreas.reiter@umm.de
-
Mannheim, Germany, 68161
- Recruiting
- Mannheim, Onkologiepraxis
-
Contact:
- Manfred Hensler, MD
- Phone Number: +49621-22430
- Email: info@mannheimer-onkologie-praxis.de
-
Memmingen, Germany, 87700
- Recruiting
- Memmingen, Onkologiepraxis
-
Contact:
- Juergen Jaeckle, MD
- Phone Number: +498331 75049-00
- Email: jaeckle@onkologie-mm.de
-
Minden, Germany, 32429
- Recruiting
- Mühlenkreiskliniken Minden
-
Contact:
- Martin Griesshammer, MD
- Phone Number: +495717901184
- Email: martin.griesshammer@muehlenkreiskliniken.de
-
Mutlangen, Germany, 73557
- Recruiting
- Stauferklinikum Schwäbisch Gmünd
-
Contact:
- Holger Hebart, MD
- Phone Number: +4971717011397
- Email: holger.hebart@kliniken-ostalb.de
-
Stuttgart, Germany, 70176
- Recruiting
- Diakonie-Klinikum Stuttgart
-
Contact:
- Jochen Greiner, MD
- Phone Number: +497119913517
- Email: greiner@diak-stuttgart.de
-
Stuttgart, Germany, 70376
- Recruiting
- Stuttgart, MVZ am RBK
-
Contact:
- Ulrike Schwinger, MD
- Phone Number: 0711-8101-5983
- Email: ulrike.schwinger@rbk-mvz.de
-
Ulm, Germany, 89081
- Recruiting
- Universitatsklinikum Ulm
-
Contact:
- Frank Stegelmann, MD
- Phone Number: 45928 +49731500
- Email: frank.stegelmann@uniklinik-ulm.de
-
Winnenden, Germany, 71334
- Recruiting
- Rems-Murr-Kliniken Winnenden
-
Contact:
- Julia Glueck-Wolf
- Phone Number: +49719559136031
- Email: julia.glueck-wolf@rems-murr-kliniken.de
-
Würzburg, Germany, 97080
- Recruiting
- Würzburg / Kitzingen, Gemeinschaftspraxis Dr. Schlag
-
Contact:
- Bjoern Schoettker, MD
- Phone Number: +49931322670
- Email: b.schoettker@onkopraxis-wuerzburg.de
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
Both female and male patients meeting the mentioned inclusion criteria will be included in this registry, because the risk to get a myeloid neoplasm does not depend on a patient's gender. Patients must meet all of the following inclusion criteria to be eligible for enrollment into the registry:
- Patients with BCR-ABL 1-myeloid neoplasia according to WHO classification or IWG MRI criteria
- Age ≥ 18 years. There is no upper age limit.
- Signed written informed consent.
Exclusion Criteria:
- Severe neurological or psychiatric disorder interfering with ability to give an informed consent
- No consent for registration, storage and handling of the personal data
Study Plan
How is the study designed?
Design Details
- Observational Models: Case-Only
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Treatment decision
Time Frame: 25 years
|
Treatment decision (watch and wait, standard, investigational)
|
25 years
|
|
Response
Time Frame: 25 years
|
Response of treatment
|
25 years
|
|
Overall survival
Time Frame: 25 years
|
Survival over the whole study duration
|
25 years
|
|
Progression-free-survival
Time Frame: 25 years
|
Survival without any progression
|
25 years
|
|
Duration of response
Time Frame: 25 years
|
Duration of response over the whole study duration
|
25 years
|
|
Quality of life assessed by the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF Protocol 5/25/11, EORTC QLQ-C30, FACT-Lym (Fassung 4)), supplemented by information on self-assessed concomitant diseases and demographics.
Time Frame: 25 years
|
Quality of life assessed by the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF Protocol 5/25/11, EORTC QLQ-C30, FACT-Lym (Fassung 4)), supplemented by information on self-assessed concomitant diseases and demographics.
|
25 years
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- MPN Registry - Ulm
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on BCR-ABL1-Negative Myeloid Neoplasms
-
NCT02092324CompletedChronic Neutrophilic Leukemia | Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative
-
NCT02381548TerminatedAcute Myeloid Leukemia | Recurrent Adult Acute Myeloid Leukemia | Secondary Acute Myeloid Leukemia | Myelodysplastic Syndrome | Refractory Acute Myeloid Leukemia | Blast Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive | Acute Myeloid Leukemia Post Cytotoxic Therapy | Recurrent Chronic Myeloid Leukemia, BCR-ABL1 Positive | Refractory Chronic Myeloid Leukemia, BCR-ABL1 Positive
-
NCT02210858CompletedChronic Myelomonocytic Leukemia | Recurrent Disease | Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable | Accelerated Phase of Disease | Chronic Phase of Disease
-
NCT04188405Active, not recruitingAcute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
-
NCT01428635CompletedPrimary Myelofibrosis | Thrombocytopenia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
-
NCT01904136CompletedAcute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome | Myelodysplastic Syndrome | Recurrent Acute Myeloid Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Therapy-Related Acute Myeloid Leukemia | de Novo Myelodysplastic Syndrome | Acute Myeloid Leukemia With Gene Mutations | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
-
NCT01746836RecruitingRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
-
NCT02730195TerminatedRecurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Chronic Myelogenous Leukemia, BCR-ABL1 Positive
-
NCT04216563TerminatedPhiladelphia Chromosome Negative, BCR-ABL1 Positive Chronic Myelogenous Leukemia
-
NCT03147612Active, not recruitingAcute Lymphoblastic Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Acute Lymphoblastic Leukemia | Refractory Acute Lymphoblastic Leukemia | Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Acute Myeloid Leukemia With BCR-ABL1
Clinical Trials on Registry study
-
NCT02285582RecruitingRare Histiocytic Disorders (RHDs) | Erdheim-Chester Disease (ECD) | Rosai-Dorfman Disease (RDD) | Xanthogranuloma Family (XG) | Indeterminate Dendritic Cell Histiocytosis | Malignant Histiocytic Neoplasm (MHN) | ALK-positive Histiocytosis | Mixed Histiocytosis (MXH) | Multicentric Reticulohistiocytoma (MRH) | Necrobiotic Xanthogranuloma (NX)
-
NCT04657367RecruitingObesity | Diabetes | PreDiabetes | Dysglycemia
-
NCT05497518RecruitingChronic Kidney Disease | Dialysis | Kidney Transplant
-
NCT00965861TerminatedMelanoma | Lymphoma | Multiple Myeloma | Myelodysplastic Syndrome
-
NCT05871762Recruiting
-
NCT05622409RecruitingPrimary Malignant Brain Tumors
-
NCT00443274Active, not recruiting
-
NCT05541380Active, not recruiting